PDF(Pubmed)
Abstract：
UNASSIGNED: Today, survivin is known as one of the most specific cancer proteins; provide unique and practical study opportunities. Clinical value of survivin in gastric cancer (GC) is not yet appointed. To establish the expression level of survivin and its diagnosis value in Iranian patients with GC, we evaluated the association of survivin expression with clinicopathologic factors.
UNASSIGNED: Overall, 60 matched-normal controls with 60 GC samples including 30 cases with evidence of metastasis at time of our study and 30 cases without evidence of metastasis were recruited, in Tehran, Iran during 2008 to 2018. Survivin expression was evaluated by quantitative Real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC) study.
UNASSIGNED: Increased expression of survivin at mRNA and protein levels was found in 86.7% and 71.6% of cases, respectively. Evidence indicated a significant difference in survivin mRNA expression level between tumor and nontumoral (marginal) tissues (P<0.001). The difference in expression of survivin mRNA was not significant between metastatic and non-metastatic tumor tissues (P=0.171). Positive immunoreactivity of survivin was observed to be predominantly in the nucleus of tumor cells. A significant difference in survivin protein expression was detected between tumor and non-tumoral tissues (P<0.001) and between metastatic and non-metastatic tumor tissues (P<0.001). There was no significant association between survivin mRNA expression and clinicopathological variables. However, survivin protein expression was significantly correlated with perineural involvement (P<0.018).
UNASSIGNED: This data could be supportive of using survivin as a useful diagnostic marker in GC. Although, more research is needed in this area.
UNASSIGNED: Overall, 60 matched-normal controls with 60 GC samples including 30 cases with evidence of metastasis at time of our study and 30 cases without evidence of metastasis were recruited, in Tehran, Iran during 2008 to 2018. Survivin expression was evaluated by quantitative Real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC) study.
UNASSIGNED: Increased expression of survivin at mRNA and protein levels was found in 86.7% and 71.6% of cases, respectively. Evidence indicated a significant difference in survivin mRNA expression level between tumor and nontumoral (marginal) tissues (P<0.001). The difference in expression of survivin mRNA was not significant between metastatic and non-metastatic tumor tissues (P=0.171). Positive immunoreactivity of survivin was observed to be predominantly in the nucleus of tumor cells. A significant difference in survivin protein expression was detected between tumor and non-tumoral tissues (P<0.001) and between metastatic and non-metastatic tumor tissues (P<0.001). There was no significant association between survivin mRNA expression and clinicopathological variables. However, survivin protein expression was significantly correlated with perineural involvement (P<0.018).
UNASSIGNED: This data could be supportive of using survivin as a useful diagnostic marker in GC. Although, more research is needed in this area.
摘要：
■今天,survivin被称为最具体的癌症蛋白质之一;提供独特和实用的研究机会。生存素在胃癌（GC）中的临床价值尚未确定。目的建立Survivin在伊朗GC患者中的表达水平及其诊断价值,我们评估了survivin表达与临床病理因素的相关性.
■总的来说，招募60个匹配的正常对照和60个GC样本，包括30个在我们研究时具有转移证据的病例和30个没有转移证据的病例。在德黑兰,伊朗2008年至2018年。通过定量实时聚合酶链反应（qRT-PCR）和免疫组织化学（IHC）研究评估Survivin的表达。
■在86.7％和71.6％的病例中发现survivin在mRNA和蛋白质水平上的表达增加，分别。证据表明肿瘤组织和非肿瘤组织(边缘组织)之间survivinmRNA表达水平存在显著差异(P<0.001)。survivinmRNA在转移和非转移肿瘤组织中的表达差异无统计学意义（P=0.171）。观察到survivin的阳性免疫反应性主要在肿瘤细胞核中。在肿瘤组织和非肿瘤组织之间以及在转移性和非转移性肿瘤组织之间检测到survivin蛋白表达的显著差异(P<0.001)。survivinmRNA表达与临床病理变量之间没有显着关联。然而,survivin蛋白表达与神经受累显著相关(P<0.018)。
■这些数据可能支持使用survivin作为GC的有用诊断标记。虽然,在这方面需要更多的研究。
■总的来说，招募60个匹配的正常对照和60个GC样本，包括30个在我们研究时具有转移证据的病例和30个没有转移证据的病例。在德黑兰,伊朗2008年至2018年。通过定量实时聚合酶链反应（qRT-PCR）和免疫组织化学（IHC）研究评估Survivin的表达。
■在86.7％和71.6％的病例中发现survivin在mRNA和蛋白质水平上的表达增加，分别。证据表明肿瘤组织和非肿瘤组织(边缘组织)之间survivinmRNA表达水平存在显著差异(P<0.001)。survivinmRNA在转移和非转移肿瘤组织中的表达差异无统计学意义（P=0.171）。观察到survivin的阳性免疫反应性主要在肿瘤细胞核中。在肿瘤组织和非肿瘤组织之间以及在转移性和非转移性肿瘤组织之间检测到survivin蛋白表达的显著差异(P<0.001)。survivinmRNA表达与临床病理变量之间没有显着关联。然而,survivin蛋白表达与神经受累显著相关(P<0.018)。
■这些数据可能支持使用survivin作为GC的有用诊断标记。虽然,在这方面需要更多的研究。
